Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levofloxacin, a second-generation fluoroquinolone

D S North1, D N Fish, J J Redington

  • 1Pharmacy Service, Denver VA Medical Center, Colorado 80220, USA.

Pharmacotherapy
|October 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit.

Journal of clinical pharmacy and therapeutics·2014
Same author

Pharmacodynamic modelling of intravenous antibiotic prophylaxis in elective colorectal surgery.

International journal of antimicrobial agents·2012
Same author

Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry.

Journal of chemotherapy (Florence, Italy)·2009
Same author

Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.

The Journal of hospital infection·2004
Same author

Hydroxyurea in the treatment of HIV infection.

The AIDS reader·2003
Same author

Cidofovir.

The AIDS reader·2003
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Levofloxacin offers an extended spectrum of activity, including improved efficacy against gram-positive bacteria and atypical organisms. This fluoroquinolone antibiotic demonstrates impressive clinical effectiveness for various infections and is generally well-tolerated.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Levofloxacin is a fluoroquinolone antibiotic approved in 1996.
  • It presents an extended spectrum of activity compared to older fluoroquinolones.
  • Levofloxacin exhibits enhanced efficacy against Gram-positive bacteria and atypical organisms.

Purpose of the Study:

  • To evaluate the efficacy and safety of levofloxacin.
  • To compare levofloxacin's activity with older fluoroquinolones.
  • To assess levofloxacin's pharmacokinetic profile.

Main Methods:

  • Clinical studies were conducted to assess efficacy in various infections.
  • Pharmacokinetic parameters were analyzed, including bioavailability and elimination.
  • Adverse events and drug interactions were monitored.

Related Experiment Videos

Main Results:

  • Levofloxacin demonstrated impressive efficacy in community-acquired pneumonia, bronchitis exacerbations, sinusitis, skin infections, and urinary tract infections.
  • The oral bioavailability of levofloxacin is nearly 100%, with a plasma elimination half-life of 6-8 hours.
  • Adverse events were similar to other fluoroquinolones, primarily gastrointestinal and central nervous system effects. Drug interactions are uncommon, but absorption is reduced by antacids or cation-containing agents.

Conclusions:

  • Levofloxacin is an effective antibiotic for treating a range of bacterial infections, including those caused by penicillin-resistant pneumococci.
  • Its pharmacokinetic profile and tolerability support its use in clinical practice.
  • Levofloxacin offers an improved therapeutic option compared to older fluoroquinolones.